Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
24
RCUS Quote, Financials, Valuation and Earnings
Last price:
$23.11
Seasonality move
:
-9.85%
Day range:
$22.53 - $23.16
52-week range:
$6.50 - $26.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.71x
P/B ratio:
6.56x
Volume:
444.8K
Avg. volume:
2.1M
1-year change:
45.32%
Market cap:
$2.9B
Revenue:
$258M
EPS (TTM):
-$3.43
Analysts' Opinion
-
Consensus RatingArcus Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $32.10, Arcus Biosciences, Inc. has an estimated upside of 38.84% from its current price of $23.12.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $23.12.
Fair Value
-
According to the consensus of 11 analysts, Arcus Biosciences, Inc. has 38.84% upside to fair value with a price target of $32.10 per share.
RCUS vs. S&P 500
-
Over the past 5 trading days, Arcus Biosciences, Inc. has overperformed the S&P 500 by 2.31% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Arcus Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Arcus Biosciences, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Arcus Biosciences, Inc. reported revenues of $26M.
Earnings Growth
-
Arcus Biosciences, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Arcus Biosciences, Inc. reported earnings per share of -$1.27.
Enterprise value:
2.1B
EV / Invested capital:
3.91x
Price / LTM sales:
9.71x
EV / EBIT:
--
EV / Revenue:
8.92x
PEG ratio (5yr expected):
-0.77x
EV / Free cash flow:
-4.61x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$230M
Return On Assets:
-30.41%
Net Income Margin (TTM):
-142.08%
Return On Equity:
-66.45%
Return On Invested Capital:
-55.66%
Operating Margin:
-546.15%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $119.7M | $263M | $240M | $48M | $26M | |
| Gross Profit | $105.2M | $251M | $230M | $46M | $24M | |
| Operating Income | -$323.4M | -$298M | -$375M | -$105M | -$142M | |
| EBITDA | -$309M | -$286M | -$365M | -$103M | -$140M | |
| Diluted EPS | -$4.00 | -$3.15 | -$3.43 | -$1.01 | -$1.27 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $545.3M | $1.1B | $881M | $1.1B | $857M | |
| Total Assets | $839.3M | $1.4B | $1.2B | $1.3B | $974M | |
| Current Liabilities | $142.9M | $177.2M | $200M | $215M | $235M | |
| Total Liabilities | $296.7M | $695.1M | $671M | $687M | $538M | |
| Total Equity | $542.6M | $698.7M | $520M | $565M | $436M | |
| Total Debt | $48.9M | $119.2M | -- | $47M | $98M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$287.7M | -$158M | -$462M | $26M | -$97M | |
| Cash From Investing | $212.8M | -$107M | $299M | -$29M | $79M | |
| Cash From Financing | $41.2M | $282M | $200M | $48M | $8M | |
| Free Cash Flow | -$306.1M | -$169M | -$464M | $25M | -$97M | |
RCUS
Sector
Market Cap
$2.9B
$28.1M
Price % of 52-Week High
87.58%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-12.08%
-1.49%
1-Year Price Total Return
45.32%
-17.13%
Beta (5-Year)
0.747
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$22.43
200-day SMA
Buy
Level
$12.66
Bollinger Bands (100)
Buy
Level
11.22 - 21.9
Chaikin Money Flow
Sell
Level
-1.7M
20-day SMA
Sell
Level
$24.09
Relative Strength Index (RSI14)
Buy
Level
52.96
ADX Line
Buy
Level
28.2
Williams %R
Neutral
Level
-54.2149
50-day SMA
Buy
Level
$21.33
MACD (12, 26)
Buy
Level
5.98
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Sell
Level
-2.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.0197)
Sell
CA Score
(Annual)
Level (-1.9794)
Buy
Beneish M-Score
(Annual)
Level (-2.5882)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (1.5024)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Stock Forecast FAQ
In the current month, RCUS has received 9 Buy ratings 2 Hold ratings, and 0 Sell ratings. The RCUS average analyst price target in the past 3 months is $32.10.
-
Where Will Arcus Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Arcus Biosciences, Inc. share price will rise to $32.10 per share over the next 12 months.
-
What Do Analysts Say About Arcus Biosciences, Inc.?
Analysts are divided on their view about Arcus Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arcus Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Arcus Biosciences, Inc.'s Price Target?
The price target for Arcus Biosciences, Inc. over the next 1-year time period is forecast to be $32.10 according to 11 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is RCUS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Arcus Biosciences, Inc. is a Buy. 9 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RCUS?
You can purchase shares of Arcus Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arcus Biosciences, Inc. shares.
-
What Is The Arcus Biosciences, Inc. Share Price Today?
Arcus Biosciences, Inc. was last trading at $23.11 per share. This represents the most recent stock quote for Arcus Biosciences, Inc.. Yesterday, Arcus Biosciences, Inc. closed at $23.12 per share.
-
How To Buy Arcus Biosciences, Inc. Stock Online?
In order to purchase Arcus Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RCUS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RCUS
Sector
P/E ratio
--
23.89x
PEG ratio
-0.77x
-0.01x
P/B ratio
6.56x
1.81x
Price / LTM sales
9.71x
1.59x
Growth Metrics
RCUS
Sector
Revenue growth
-45.83%
4.62%
Earnings growth
-25.93%
11.06%
Revenue (5-year growth)
76.65%
6.5%
Earnings forecast
-$1.29
-$0.21
Profitability
RCUS
Sector
Profitability FY 2024
$248M
$3.6M
Return on invested capital
-55.66%
-31.84%
Return on assets
-30.41%
-27.96%
Return on equity
-66.45%
-37.63%
Earnings Date
Last Earnings Date
Oct
28
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Jan
27
Balance Sheet
RCUS
Sector
Total cash
$831M
$26.4M
Short term investments
$828M
$25.7M
Total assets
$1.2B
$76.9M
Long term debt
$98M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
87
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
60
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
